ESR1 and breast carcinoma: A tight link between luminal estrogen receptor (ER)+ and basal ER- breast tumors is also suggested by the observation that antihormonal treatment of ER+ breast cancer patients with tamoxifen treatment increases risk of contralateral development of ER- tumors [9].